Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2022-01-28 00:00:00 ET · period of report 2022-01-26 · accession 0000874015-22-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-01-28 | 2022-01-26 | IONS | Monia Brett P | CEO, Dir | A - Grant | $0.00 | +16.2K | 96.4K | +20% | $0 |
| 2022-01-28 | 2022-01-26 | IONS | Monia Brett P | CEO, Dir | F - Tax | $31.44 | -8,032 | 88.4K | -8% | -$252.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-26 | A | A | 2,194 | $0.00 | 82,424 | D | — | — | (F1) Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 58.06% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. |
| 2 | Common | Common Stock | 2022-01-26 | F | D | 8,032 | $31.44 | 88,396 | D | — | — | (F3) Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. |
| 3 | Common | Common Stock | 2022-01-26 | A | A | 14,004 | $0.00 | 96,428 | D | — | — | (F2) Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 81.37% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. |